Dignify Therapeutics, a pharmaceutical and medical device development company in Research Triangle Park focused on restoring bowel and bladder control for elderly and neurologically impaired people, has added a new compound to its product pipeline.
Dignify Therapeutics, a pharmaceutical and medical device development company in Research Triangle Park, has received a major federal award to advance its main drug candidate for treating bladder and bowel dysfunction.
by Bryant Haskins, NCBiotech Writer May 3, 2021 .
Editor’s note: Startup Spotlight is a regular part of WRAL TechWire’s Startup Monday package that includes our Jobs Report, Startup Guide updates, previews of local and North Carolina events, a recap of the previous week’s startup-related headlines, and a comprehensive list of meetups across the Triangle.
RESEARCH TRIANGLE PARK – A new North Carolina-based biopharmaceutical company with a focus on rare illnesses hopes to be the first to find a treatment for Farber disease.
This extremely rare genetic disorder results in the buildup of a material in the body called ceramide that can inflame and damage many different tissues. Joints, connective tissue, the lungs and central nervous system are often impacted. Patients with Farber disease are profoundly affected and the illness often can lead to death in childhood.
.
A new North Carolina-based biopharmaceutical company with a focus on rare illnesses hopes to be the first to find a treatment for Farber disease.
This extremely rare genetic disorder results in the buildup of a material in the body called ceramide that can inflame and damage many different tissues. Joints, connective tissue, the lungs and central nervous system are often impacted. Patients with Farber disease are profoundly affected and the illness often can lead to death in childhood.
Aceragen, which launched in January 2021, has acquired an investigational therapy – ACG-801 – from Enzyvant, another biotech company with a significant presence in North Carolina. The product was developed from foundational research by Edward Schuchman, Ph.D., a professor at the Icahn School of Medicine at Mount Sinai in New York City.